135 related articles for article (PubMed ID: 38793681)
1. Evaluation of a Project Integrating Financial Incentives into a Hepatitis C Testing and Treatment Model of Care at a Sexual Health Service in Cairns, Australia, 2020-2021.
Dawe J; Gorton C; Lewis R; Richmond JA; Wilkinson AL; Pedrana A; Stoové M; Doyle JS; Russell D
Viruses; 2024 May; 16(5):. PubMed ID: 38793681
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022.
Dawe J; Hughes M; Christensen S; Walsh L; Richmond JA; Pedrana A; Wilkinson AL; Owen L; Doyle JS;
BMC Public Health; 2023 Nov; 23(1):2289. PubMed ID: 37985979
[TBL] [Abstract][Full Text] [Related]
3. Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults (The Methodical evaluation and Optimisation of Targeted IncentiVes for Accessing Treatment of Early-stage hepatitis C: MOTIVATE-C): protocol for a dose-response randomised controlled study.
Fathima P; Jones M; D'Souza R; Totterdell J; Andric N; Abbott P; Norman R; Howard K; Cheng W; Pedrana A; Doyle JS; Davies J; Snelling T
Trials; 2024 Jun; 25(1):387. PubMed ID: 38886819
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.
MacIsaac MB; Whitton B; Anderson J; Cogger S; Vella-Horne D; Penn M; Weeks A; Elmore K; Pemberton D; Winter RJ; Papaluca T; Howell J; Hellard M; Stoové M; Wilson D; Pedrana A; Doyle JS; Clark N; Holmes JA; Thompson AJ
Int J Drug Policy; 2024 Mar; 125():104317. PubMed ID: 38281385
[TBL] [Abstract][Full Text] [Related]
5. Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.
MacIsaac MB; Whitton B; Hubble A; Cogger S; Penn M; Weeks A; Elmore K; Pemberton D; Anderson J; Howard R; McKeever U; Papaluca T; Hellard ME; Stoove M; Wilson D; Pedrana A; Doyle J; Clark N; Holmes J; Thompson AJ
Med J Aust; 2023 Apr; 218(6):256-261. PubMed ID: 36919230
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system.
Gibbs D; Price O; Grebely J; Larney S; Sutherland R; Read P; Butler K; Degenhardt L; Peacock A
Drug Alcohol Depend; 2021 Nov; 228():109050. PubMed ID: 34607193
[TBL] [Abstract][Full Text] [Related]
7. The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
Wade AJ; Macdonald DM; Doyle JS; Gordon A; Roberts SK; Thompson AJ; Hellard ME
PLoS One; 2015; 10(11):e0142770. PubMed ID: 26562516
[TBL] [Abstract][Full Text] [Related]
8. A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY; Chan K; Gold J; Layton C; Elsum I; Hellard M; Stoove M; Doyle JS; Pedrana A; Scott N;
J Viral Hepat; 2021 Nov; 28(11):1624-1634. PubMed ID: 34415639
[TBL] [Abstract][Full Text] [Related]
9. A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia.
Harney BL; Whitton B; Paige E; Brereton R; Weiss R; Membrey D; Wade AJ; Iser D; Kemp W; Roberts SK; Spelman T; Sacks-Davis R; Hellard ME; Doyle JS
Liver Int; 2022 Mar; 42(3):522-531. PubMed ID: 34821021
[TBL] [Abstract][Full Text] [Related]
10. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
[TBL] [Abstract][Full Text] [Related]
11. Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department.
Hutton J; Doyle J; Zordan R; Weiland T; Cocco A; Howell J; Iser S; Snell J; Fry S; New K; Sloane R; Jarman M; Phan D; Tran S; Pedrana A; Williams B; Johnson J; Glasgow S; Thompson A
Int J Drug Policy; 2019 Oct; 72():84-90. PubMed ID: 31351752
[TBL] [Abstract][Full Text] [Related]
12. Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial.
Day CA; Shanahan M; Wand H; Topp L; Haber PS; Rodgers C; Deacon R; Walsh N; Kaldor J; van Beek I; Maher L;
J Clin Virol; 2016 Jan; 74():66-72. PubMed ID: 26679830
[TBL] [Abstract][Full Text] [Related]
13. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
16. The eliminate hepatitis C (EC) experience study: baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia.
Gunn J; O'Keefe D; Draper BL; Djordjevic F; Ryan K; Kerr P; Elsum I; Gold J; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana A
BMJ Open; 2023 Jul; 13(7):e071665. PubMed ID: 37400235
[TBL] [Abstract][Full Text] [Related]
17. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia.
Topp L; Day CA; Wand H; Deacon RM; van Beek I; Haber PS; Shanahan M; Rodgers C; Maher L;
Prev Med; 2013 Oct; 57(4):297-303. PubMed ID: 23639625
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
Bajis S; Grebely J; Cooper L; Smith J; Owen G; Chudleigh A; Hajarizadeh B; Martinello M; Adey S; Read P; Gilliver R; Applegate T; Treloar C; Maher L; Dore GJ
J Viral Hepat; 2019 Aug; 26(8):969-979. PubMed ID: 30980785
[TBL] [Abstract][Full Text] [Related]
19. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
20. Exploring hepatitis C virus testing and treatment engagement over time in Melbourne, Australia: a study protocol for a longitudinal cohort study (EC-Experience Cohort study).
O'Keefe D; Gunn J; Ryan K; Djordjevic F; Kerr P; Gold J; Elsum I; Layton C; Chan K; Dietze P; Higgs P; Doyle J; Stoové MA; Hellard M; Pedrana AE
BMJ Open; 2022 Jan; 12(1):e057618. PubMed ID: 34983773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
